Infralimbic D2 receptor influences on anxiety-like behavior and active memory/attention in CD-1 mice

Philip M. Wall, Robert J. Blanchard, Mu Yang, D. Caroline Blanchard

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Ventromedial prefrontal cortical (vmPFC) dopamine (DA) influences attentional aspects of cognition and anxiety-like behavioral responding in rodents. The present study investigated the role of D2 receptors on spontaneous alternation in the Y-maze and anxiety-like behavior in a two-trial elevated plus-maze (EPM) procedure in CD-1 mice following vmPFC infusions of the D2 antagonist, sulpiride, and the D2 agonist, quinpirole. Pretrial 1 quinpirole infusions did not influence any anxiety measure (with the exception that the lowest dose increased protected stretch attends), but reduced protected exploration activity (closed-arm entry/time ratios and wall rearing). In Trial 2 24 h later (no injection), quinpirole exerted an anxiolytic behavioral profile relative to Trial 2 control mice (enhanced open-arm entry/time ratios, unprotected head dips), with no effects on protected exploration or risk assessment activity. Pretrial 1 sulpiride infusions enhanced unprotected exploration (open-arm entry/time ratios, unprotected stretch attend, and head dips), but did not influence protected exploration or risk assessment in the EPM. In Trial 2, 24 h later (no injection), sulpiride extended this anxiolytic profile to reduced protected exploration and risk assessment activity (closed-time ratio, protected stretch attend, and head dips). In the Y-maze, whereas quinpirole disrupted alternation performance (5- and 10-nmol dose) concomitant with marked repetitive same-arm returns (SAR) at the highest dose, sulpiride disrupted alternation performance concomitant with marked repetitive SAR behavior at the lowest dose only. These data indicate that although infralimbic (IL) quinpirole and sulpiride infusions similarly disrupted alternation performance in the Y-maze and reduced Trial 2 anxiety-like responding in the EPM, these drugs differentially produced these effects.

Original languageEnglish (US)
Pages (from-to)395-410
Number of pages16
JournalProgress in Neuro-Psychopharmacology and Biological Psychiatry
Volume27
Issue number3
DOIs
StatePublished - May 2003
Externally publishedYes

Fingerprint

Quinpirole
Sulpiride
Arm
Anxiety
Head
Anti-Anxiety Agents
Injections
Cognition
Rodentia
Dopamine
Pharmaceutical Preparations

Keywords

  • Active working memory
  • Anxiety
  • Attention
  • D2 receptors
  • Dopamine
  • Elevated plus-maze
  • Infralimbic ventromedial prefrontal cortex
  • Risk assessment
  • Y-maze

ASJC Scopus subject areas

  • Biological Psychiatry
  • Pharmacology

Cite this

Infralimbic D2 receptor influences on anxiety-like behavior and active memory/attention in CD-1 mice. / Wall, Philip M.; Blanchard, Robert J.; Yang, Mu; Blanchard, D. Caroline.

In: Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 27, No. 3, 05.2003, p. 395-410.

Research output: Contribution to journalArticle

Wall, Philip M. ; Blanchard, Robert J. ; Yang, Mu ; Blanchard, D. Caroline. / Infralimbic D2 receptor influences on anxiety-like behavior and active memory/attention in CD-1 mice. In: Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2003 ; Vol. 27, No. 3. pp. 395-410.
@article{b7a71a8618b0424e8cca92504df9d5cd,
title = "Infralimbic D2 receptor influences on anxiety-like behavior and active memory/attention in CD-1 mice",
abstract = "Ventromedial prefrontal cortical (vmPFC) dopamine (DA) influences attentional aspects of cognition and anxiety-like behavioral responding in rodents. The present study investigated the role of D2 receptors on spontaneous alternation in the Y-maze and anxiety-like behavior in a two-trial elevated plus-maze (EPM) procedure in CD-1 mice following vmPFC infusions of the D2 antagonist, sulpiride, and the D2 agonist, quinpirole. Pretrial 1 quinpirole infusions did not influence any anxiety measure (with the exception that the lowest dose increased protected stretch attends), but reduced protected exploration activity (closed-arm entry/time ratios and wall rearing). In Trial 2 24 h later (no injection), quinpirole exerted an anxiolytic behavioral profile relative to Trial 2 control mice (enhanced open-arm entry/time ratios, unprotected head dips), with no effects on protected exploration or risk assessment activity. Pretrial 1 sulpiride infusions enhanced unprotected exploration (open-arm entry/time ratios, unprotected stretch attend, and head dips), but did not influence protected exploration or risk assessment in the EPM. In Trial 2, 24 h later (no injection), sulpiride extended this anxiolytic profile to reduced protected exploration and risk assessment activity (closed-time ratio, protected stretch attend, and head dips). In the Y-maze, whereas quinpirole disrupted alternation performance (5- and 10-nmol dose) concomitant with marked repetitive same-arm returns (SAR) at the highest dose, sulpiride disrupted alternation performance concomitant with marked repetitive SAR behavior at the lowest dose only. These data indicate that although infralimbic (IL) quinpirole and sulpiride infusions similarly disrupted alternation performance in the Y-maze and reduced Trial 2 anxiety-like responding in the EPM, these drugs differentially produced these effects.",
keywords = "Active working memory, Anxiety, Attention, D2 receptors, Dopamine, Elevated plus-maze, Infralimbic ventromedial prefrontal cortex, Risk assessment, Y-maze",
author = "Wall, {Philip M.} and Blanchard, {Robert J.} and Mu Yang and Blanchard, {D. Caroline}",
year = "2003",
month = "5",
doi = "10.1016/S0278-5846(02)00356-1",
language = "English (US)",
volume = "27",
pages = "395--410",
journal = "Progress in Neuro-Psychopharmacology and Biological Psychiatry",
issn = "0278-5846",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Infralimbic D2 receptor influences on anxiety-like behavior and active memory/attention in CD-1 mice

AU - Wall, Philip M.

AU - Blanchard, Robert J.

AU - Yang, Mu

AU - Blanchard, D. Caroline

PY - 2003/5

Y1 - 2003/5

N2 - Ventromedial prefrontal cortical (vmPFC) dopamine (DA) influences attentional aspects of cognition and anxiety-like behavioral responding in rodents. The present study investigated the role of D2 receptors on spontaneous alternation in the Y-maze and anxiety-like behavior in a two-trial elevated plus-maze (EPM) procedure in CD-1 mice following vmPFC infusions of the D2 antagonist, sulpiride, and the D2 agonist, quinpirole. Pretrial 1 quinpirole infusions did not influence any anxiety measure (with the exception that the lowest dose increased protected stretch attends), but reduced protected exploration activity (closed-arm entry/time ratios and wall rearing). In Trial 2 24 h later (no injection), quinpirole exerted an anxiolytic behavioral profile relative to Trial 2 control mice (enhanced open-arm entry/time ratios, unprotected head dips), with no effects on protected exploration or risk assessment activity. Pretrial 1 sulpiride infusions enhanced unprotected exploration (open-arm entry/time ratios, unprotected stretch attend, and head dips), but did not influence protected exploration or risk assessment in the EPM. In Trial 2, 24 h later (no injection), sulpiride extended this anxiolytic profile to reduced protected exploration and risk assessment activity (closed-time ratio, protected stretch attend, and head dips). In the Y-maze, whereas quinpirole disrupted alternation performance (5- and 10-nmol dose) concomitant with marked repetitive same-arm returns (SAR) at the highest dose, sulpiride disrupted alternation performance concomitant with marked repetitive SAR behavior at the lowest dose only. These data indicate that although infralimbic (IL) quinpirole and sulpiride infusions similarly disrupted alternation performance in the Y-maze and reduced Trial 2 anxiety-like responding in the EPM, these drugs differentially produced these effects.

AB - Ventromedial prefrontal cortical (vmPFC) dopamine (DA) influences attentional aspects of cognition and anxiety-like behavioral responding in rodents. The present study investigated the role of D2 receptors on spontaneous alternation in the Y-maze and anxiety-like behavior in a two-trial elevated plus-maze (EPM) procedure in CD-1 mice following vmPFC infusions of the D2 antagonist, sulpiride, and the D2 agonist, quinpirole. Pretrial 1 quinpirole infusions did not influence any anxiety measure (with the exception that the lowest dose increased protected stretch attends), but reduced protected exploration activity (closed-arm entry/time ratios and wall rearing). In Trial 2 24 h later (no injection), quinpirole exerted an anxiolytic behavioral profile relative to Trial 2 control mice (enhanced open-arm entry/time ratios, unprotected head dips), with no effects on protected exploration or risk assessment activity. Pretrial 1 sulpiride infusions enhanced unprotected exploration (open-arm entry/time ratios, unprotected stretch attend, and head dips), but did not influence protected exploration or risk assessment in the EPM. In Trial 2, 24 h later (no injection), sulpiride extended this anxiolytic profile to reduced protected exploration and risk assessment activity (closed-time ratio, protected stretch attend, and head dips). In the Y-maze, whereas quinpirole disrupted alternation performance (5- and 10-nmol dose) concomitant with marked repetitive same-arm returns (SAR) at the highest dose, sulpiride disrupted alternation performance concomitant with marked repetitive SAR behavior at the lowest dose only. These data indicate that although infralimbic (IL) quinpirole and sulpiride infusions similarly disrupted alternation performance in the Y-maze and reduced Trial 2 anxiety-like responding in the EPM, these drugs differentially produced these effects.

KW - Active working memory

KW - Anxiety

KW - Attention

KW - D2 receptors

KW - Dopamine

KW - Elevated plus-maze

KW - Infralimbic ventromedial prefrontal cortex

KW - Risk assessment

KW - Y-maze

UR - http://www.scopus.com/inward/record.url?scp=0037402536&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037402536&partnerID=8YFLogxK

U2 - 10.1016/S0278-5846(02)00356-1

DO - 10.1016/S0278-5846(02)00356-1

M3 - Article

VL - 27

SP - 395

EP - 410

JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry

JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry

SN - 0278-5846

IS - 3

ER -